A recent stage 2 drug study undertaken by Pulmotect, Inc., a Houston-based biotech business, revealed that it could be a viable therapy for COVID-19 or other pulmonary disorders.
Participants in the study who were given inhalation PUL-042 improved their coughing and breathlessness faster than individuals who were given a placebo. They had fewer admissions and critical care hospitalizations as well.
Inhalation Drug Shows Promising Results Against Respiratory Infections
Respiratory infections are common to people in many areas. Though it can lead to more complications in some cases, in all cases, it depends on the immunity of an individual.
A new drug is being tested by experts, which has shown good and expected results during trials. The best part of this drug is it has to be inhaled and not injected or swallowed by the patient. Hence those who are scared of such drugs may also get the required benefits.
A unique medicine is being developed that may be able to avert the next worldwide epidemic. PUL-042, an inhaled treatment that gives wide resistance from a spectrum of life-threatening pulmonary diseases, is being tested by scientists.
“We have not found a virus PUL-042 cannot work against in the lungs, in animal studies,” said Dr. Colin Broom, CEO of Pulmotect. “As an easily administered inhaled therapy, PUL-042 could have value in reducing the impact of COVID-19 irrespective of the development of further variants. It also has potential utility for other patient populations which we plan to explore, including immunosuppressed cancer patients.”
PUL-042 boosts the innate immunity systems of the airways guarding versus a wide range of pulmonary infections when inhaled. PUL-042 might be used to combat all current and potential COVID-19 viral variations and also potential epidemics.
According to the researchers behind this one, PUL-042 can be used in various patient groups depending on the positive outcomes of this experiment and outstanding performance in pre-clinical studies.
Our body’s natural initial line of defense versus intruding microorganisms is the intrinsic autoimmune condition. The innate immunity systems react rapidly to attack infections and foreign chemicals that enter the organism. PUL-042, the first medicine of its kind, is made up of two tiny synthetic compounds that act within mins to stimulate certain innate immunological receptors in the lungs membrane. Although the treatment usually lasts 3 to 4 minutes, it could be done once several times.
“The lungs are the point of entry for many viruses and bacteria. By activating the innate immune defense of the lungs, PUL-042 can provide effective protection against a wide range of deadly pathogens,” Hӧӧk said.
“We believe that if we had this therapy available in December of 2019, we could have prevented the COVID-19 pandemic and avoided the 6 million lives lost.”
Dr. Burton Dickey, head of the pulmonary department at MD Anderson Cancer Center, & Magnus Hk, regents and senior scientist at the Texas A&M Health Institute of Biosciences & Technology, developed PUL-042.
This month the Food & Drug Administration gave Pulmotect permission to commence two people research studies of PUL-042, one for COVID-19 prevention & the other for COVID-19 therapy. A US Government of Defense gave financial assistance for the experiments.
This COVID-19 epidemic is the world’s worst health care calamity in the last century. In the coming months or years, vaccinations and/or particular treatment medicines addressing SARS-CoV-2 should be accessible. Only with the rapidity & amount of COVID-19/SARS-CoV-2 work being conducted to identify viable medications & cures for the illness, we have reason should be optimistic.
While the exact biochemical processes are still unclear, anti-inflammatory/antioxidative strain, improved hypoxemia/hypoxia & antiviral activity, among other things, can be key factors. The biochemical pathways will have to be investigated more in the coming.
